Sustained release formulations BE [Design Issues]

posted by Ahmed meeran – 2006-11-21 13:24 (7152 d 04:13 ago) – Posting: # 368
Views: 7,237

Dear Dr. Helmut

Kindly advise me how to conduct BE for a sustained release formulation in UK/EU. Both the innovator and test products are sustained release formulation of same strength. Whether the studies have to be conducted in s.s.a designs. Whether Both fasting and fed BE has to be conducted. Whether BW can be applied based on the highest dose strength if IVIVC performed. If IVIVC has to be performed on what method. is it by Wagner or Loo - Reigelmann method (but no oral solution data is available) or numerical deconvulation method to be used. Kindly clarify

Sincerly,

D.Ahmed

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
143 visitors (0 registered, 143 guests [including 28 identified bots]).
Forum time: 18:37 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5